TrialArthritis & rheumatology (Hoboken, N.J.)2022

Tofacitinib and Risk of Malignancy: Results From the Safety of Tofacitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA) Study.

Farzin Khosrow-Khavar et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.